Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab for Late Antibody-Mediated Rejection in Kidney Transplant
NCT03444103Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jan 2018
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of clazakizumab in antibody mediated rejection (AMR), sponsored by Medical University of Vienna. Started Jan 2018; status: completed.
02
Drugs
clazakizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT03444103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444103.